Literature DB >> 27745754

Five-fold increased risk of relapse following breaks in antipsychotic treatment of first episode psychosis.

Toby T Winton-Brown1, Thomas Elanjithara1, Paddy Power1, Ricardo Coentre1, Pablo Blanco-Polaina1, Philip McGuire2.   

Abstract

BACKGROUND: A key problem in the management of first episode psychosis is that patients are often reluctant to take antipsychotic medication, especially once their presenting symptoms have resolved. Clinicians may be tempted to trial a 'break in treatment' in such patients. AIM: To assess the impact of interruptions in the antipsychotic treatment of first episode psychosis.
METHOD: Treatment adherence and clinical course were assessed during the 18months following presentation in 136 consecutive patients with a first episode of psychosis in 2003-2005 by a systematic retrospective casenote review. Regression analyses were used to examine the time to remission and the risk of relapse in patients who had stopped antipsychotics for one month or more.
RESULTS: There were breaks in antipsychotic treatment of ≥1month in more than half of the patients (n=73; 58%). When these occurred before they had recovered (n=22; 17%), the time to remission was almost twice as long as in patients in whom treatment was continuous (t=2.9, P=0.01). Patients in whom treatment was interrupted were 5 times more likely to have relapsed than those in whom it was continuous (p=0.0001, 95%CI 2.1-11). The mean time to relapse following an interruption in treatment was 3months.
CONCLUSION: If the treatment of first episode psychosis with antipsychotic medication is stopped for a month or more, remission may be delayed and the risk of relapse following remission may be substantially increased.
Copyright © 2016. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27745754     DOI: 10.1016/j.schres.2016.09.029

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  8 in total

1.  What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?

Authors:  Christoph U Correll; Jose M Rubio; John M Kane
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

2.  Medication adherence in first episode psychosis: the role of pre-onset subthreshold symptoms.

Authors:  J-G Daneault; A Maraj; M Lepage; A Malla; N Schmitz; S N Iyer; R Joober; J L Shah
Journal:  Acta Psychiatr Scand       Date:  2019-04       Impact factor: 6.392

3.  Improving outcomes of first-episode psychosis: an overview.

Authors:  Paolo Fusar-Poli; Patrick D McGorry; John M Kane
Journal:  World Psychiatry       Date:  2017-10       Impact factor: 49.548

4.  Lifetime relapse and its associated factors among people with schizophrenia spectrum disorders who are on follow up at Comprehensive Specialized Hospitals in Amhara region, Ethiopia: a cross-sectional study.

Authors:  Solomon Moges; Tilahun Belete; Tesfa Mekonen; Melak Menberu
Journal:  Int J Ment Health Syst       Date:  2021-05-06

5.  Predictive Factors of Treatment Resistance in First Episode of Psychosis: A Systematic Review.

Authors:  Paola Bozzatello; Silvio Bellino; Paola Rocca
Journal:  Front Psychiatry       Date:  2019-02-26       Impact factor: 4.157

6.  Early predictors for late hospitalizations up to 14 years after first episode psychosis.

Authors:  Pontus Strålin; Maria Skott; Johan Cullberg
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2020-12-02       Impact factor: 4.328

7.  Discontinuing Antipsychotic Medication After Remission from First-Episode Psychosis: A Survey of Psychiatrists' Attitudes in Taiwan.

Authors:  Ko Yen; Chen-Chung Liu; Yi-Ting Lin; Yi-Ling Chien; Ming H Hsieh; Chih-Min Liu; Tzung-Jeng Hwang; Wei-Hsiang Liao; Hai-Gwo Hwu
Journal:  Neuropsychiatr Dis Treat       Date:  2022-03-01       Impact factor: 2.570

8.  Dynamics between insight and medication adherence in first-episode psychosis: Study of 3-year trajectories.

Authors:  Julien Elowe; Julie Ramain; Alessandra Solida; Philippe Conus; Philippe Golay
Journal:  Eur Psychiatry       Date:  2022-08-15       Impact factor: 7.156

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.